In type 2 diabetes management for patients with obesity and cardiovascular risk, which medication class is associated with both benefits?

• A. DPP-4 inhibitors
• B. SGLT2 inhibitors
• C. GLP-1 receptor agonists
• D. Insulin

Answer: (C)

In type 2 diabetes, choosing a medication that not only lowers glucose but also helps with obesity and reduces cardiovascular risk offers a dual advantage in patients who are overweight and have CV concerns. GLP-1 receptor agonists do exactly that: they promote weight loss by slowing gastric emptying and reducing appetite, and they have demonstrated cardiovascular risk reduction in major trials (for example, liraglutide, semaglutide, and dulaglutide have shown lower rates of major adverse cardiovascular events in high-risk populations). This combination of meaningful weight loss plus cardiovascular benefit makes this class particularly suitable for patients with obesity and cardiovascular risk. Other options tend to be weight-neutral or even weight-gain with less consistent CV benefit data, or primarily focus on glucose lowering without the same weight and CV advantages.